Bausch + Lomb stock slides as BL1332 pain study misses its main goal
Bausch + Lomb shares fell about 5% after the BL1332 eye-pain study missed its primary 24-hour endpoint, according to StockStory. The stock later recovered part of the drop.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Bausch + Lomb, an eyecare company, saw its shares drop roughly 5% in the afternoon session after a study of its BL1332 product failed to reach its key target, StockStory reported. The trial measured pain relief over 24 hours and found no statistically meaningful advantage over the vehicle control on the combined pain intensity score. The reported differences were -11.5 for the 0.30% concentration and -9.0 for the 0.15% concentration, where negative numbers indicate stronger relief.
The shares later pared their losses and traded at $19.75, down 4.5% from the prior close. According to the outlet, the miss weakens the evidence of efficacy for BL1332 and leaves its next development steps uncertain.
why it matters
Bausch + Lomb typically trades quietly, with only three moves above 5% over the past year, so the sharp reaction suggests investors see the result as meaningful, even if it may not change their broader view of the business. The stock is up 19.1% so far this year and sits near its 52-week high of $21.37, so the trial setback could weigh on sentiment.
market impact
Bausch + Lomb: failed BL1332 trial weakens the drug's outlook, pressuring the stock
- Bausch + Lomb shares pressure down — the missed primary endpoint weakens the efficacy case for BL1332
tags
instruments
sources
- Why Bausch + Lomb shares are getting obliterated today — stockstory.org, 20 November 2026 at 18:55 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗